Last reviewed · How we verify
moderate ovarian stimulation
Moderate Ovarian Stimulation, marketed by Dr. Massin Nathalie, holds a position in the fertility treatment segment. The drug's key composition patent is set to expire in 2028, providing a period of market exclusivity. The primary risk is the potential increase in competition post-patent expiry.
At a glance
| Generic name | moderate ovarian stimulation |
|---|---|
| Also known as | ovarian stimulation |
| Sponsor | Dr Massin Nathalie |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Cohort Profile：The Shandong Adenomyosis Cohort of Population Undergoing Reproductive Technology (SAart)
- Physical Activity and Fertility Care Study (NA)
- HRT Versus MOS for Endometrial Preparation Prior to FET in Non PCOS Patients (PHASE4)
- HMG Stimulation Versus HRT for Endometrial Preparation Prior to Blastocyst Transfer in Moderate to Severe IUA Patients (NA)
- Natural Cycle Versus Stimulated Cycle Before Frozen Embryo Transfer (PHASE4)
- HRT Versus MOS for Endometrial Preparation Prior to FET in PCOS Patients
- Acupuncture in the Regulation of Dai Meridian for Polycystic Ovarian Syndrome Patients With Abdominal Obesity (NA)
- Effect of Increased Circulating Androgens on Granulosa Cell Responses to FSH. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |